Literature DB >> 21621004

Immunization in the adult immunocompromised host.

Micha Löbermann1, Denise Boršo, Inken Hilgendorf, Carlos Fritzsche, Uwe K Zettl, Emil C Reisinger.   

Abstract

The number of patients with impaired immune response has been steadily increasing within the last years, not only with the onset of the AIDS epidemic, but also due to increasing numbers of subjects on immunosuppressive therapies. These patients are at an increased risk for infections, many of which are preventable by immunization. Inactivated vaccines are generally safe in subjects with underlying immunosuppression. However, immune response and protection may be hampered, depending on the extent of immunosuppression. In contrast, live vaccines such as yellow fever, measles, rubella, herpes zoster, and cholera may lead to severe reactions in immunocompromised patients and have been shown to deteriorate some immune-mediated diseases such as multiple sclerosis. Data on the efficacy of vaccines in biological therapies is scarce. Where necessary vaccines should be updated before immunosuppressive therapies are started. To improve the vaccination status several guidelines exist for immunosuppressed patients at risk such as those with rheumatic diseases, asplenia or solid organ and hematopoietic stem cell transplantation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621004     DOI: 10.1016/j.autrev.2011.05.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

2.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

3.  [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

4.  Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.

Authors:  Avinash K Shetty; Mary A Winter
Journal:  Ochsner J       Date:  2012

Review 5.  Zeroing in on zoster: A tale of many disorders produced by one virus.

Authors:  Kristin M Galetta; Don Gilden
Journal:  J Neurol Sci       Date:  2015-10-03       Impact factor: 3.181

6.  Specialized Proresolving Mediators Overcome Immune Suppression Induced by Exposure to Secondhand Smoke.

Authors:  Tariq A Bhat; Suresh Gopi Kalathil; Austin Miller; Thomas H Thatcher; Patricia J Sime; Yasmin Thanavala
Journal:  J Immunol       Date:  2020-10-28       Impact factor: 5.422

7.  Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study.

Authors:  Andinet Alemu; Maharaj Singh; Chris Blumberg; John O Richards; Martin K Oaks; Michael A Thompson
Journal:  J Patient Cent Res Rev       Date:  2017-04-25

8.  AT-RvD1 Mitigates Secondhand Smoke-Exacerbated Pulmonary Inflammation and Restores Secondhand Smoke-Suppressed Antibacterial Immunity.

Authors:  Tariq A Bhat; Suresh Gopi Kalathil; Paul N Bogner; Paul V Lehmann; Thomas H Thatcher; Patricia J Sime; Yasmin Thanavala
Journal:  J Immunol       Date:  2021-02-08       Impact factor: 5.422

Review 9.  [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Authors:  Tobias Monschein; Tobias Zrzavy; Micha Löbermann; Alexander Winkelmann; Thomas Berger; Paulus Rommer; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nervenarzt       Date:  2021-07-07       Impact factor: 1.297

Review 10.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.